Research programme: allergy immunotherapies - Sementis

Drug Profile

Research programme: allergy immunotherapies - Sementis

Alternative Names: SCV 204; SCV 209

Latest Information Update: 05 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sementis
  • Class Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity

Most Recent Events

  • 03 Feb 2016 Preclinical trials in Hypersensitivity in Australia (unspecified route)
  • 02 Feb 2016 University of South Australia and Sementis agree to co-develop allergy immunotherapies before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top